Table 2.

Association of IGF-I, IGFBP-3, and molar IGF-I/IGFBP-3 ratio with risk of gliomas, meningiomas, and acoustic neuromas in EPIC, 1994–2006

GliomaMeningiomaAcoustic neuroma
CategoryaCases/controlsORb (95% CI)ORc (95% CI)Cases/controlsORb (95% CI)ORc (95% CI)Cases/controlsORb (95% CI)ORc (95% CI)
IGF-I
 158/1261.001.0037/871.001.0012/481.001.00
 288/1421.37 (0.90, 2.11)1.31 (0.84–2.05)41/831.20 (0.70–2.07)1.05 (0.60–1.86)16/312.73 (0.98–7.62)1.54 (0.48–4.92)
 361/1550.85 (0.54–1.36)0.81 (0.49–1.35)50/791.53 (0.88–2.67)1.20 (0.65–2.23)21/186.63 (2.27–19.4)3.56 (1.02–12.5)
 475/1351.19 (0.74–1.90)1.16 (0.66–2.04)46/1011.14 (0.63–2.05)0.80 (0.40–1.61)
log21.14 (0.80–1.62)1.43 (0.90–2.28)1.12 (0.74–1.69)0.81 (0.46–1.43)4.50 (1.79–11.3)2.42 (0.73–7.96)
Exclude first year of follow-up
 153/1111.001.0033/801.001.0010/411.001.00
 277/1271.28 (0.81–2.01)1.21 (0.76–1.95)37/721.31 (0.74–2.32)1.12 (0.61–2.04)13/272.26 (0.77–6.61)1.33 (0.39–4.51)
 357/1430.82 (0.50–1.33)0.78 (0.45–1.32)47/731.61 (0.90–2.87)1.22 (0.64–2.32)19/156.93 (2.24–21.51)3.81 (1.04–13.99)
 469/1261.11 (0.68–1.81)1.09 (0.60–1.97)42/951.13 (0.61–2.09)0.77 (0.37–1.60)
log21.13 (0.78–1.62)1.46 (0.91–2.36)1.13 (0.73–1.75)0.84 (0.46–1.51)5.08 (1.84–14.01)2.84 (0.78–10.32)
IGFBP-3
 166/1451.001.0031/811.001.008/411.001.00
 276/1331.24 (0.83–1.85)1.22 (0.80–1.88)41/841.35 (0.76–2.42)1.30 (0.70–2.42)17/333.22 (1.11–9.35)2.74 (0.90–8.35)
 375/1381.18 (0.77–1.81)1.21 (0.75–1.97)52/931.62 (0.90–2.92)1.65 (0.85–3.19)24/237.07 (2.32–21.6)4.06 (1.13–14.6)
 465/1450.97 (0.62–1.51)0.95 (0.56–1.62)52/921.63 (0.90–2.97)1.85 (0.91–3.76)
log20.83 (0.52–1.32)0.62 (0.33–1.15)1.59 (0.84–3.02)2.09 (0.87–5.01)9.36 (2.45–35.8)3.94 (0.69–22.5)
Exclude first year of follow-up
 160/1311.0027/751.007/361.001.00
 270/1161.30 (0.85–1.98)1.31 (0.83–2.08)38/741.56 (0.83–2.91)1.50 (0.77–2.91)15/273.03 (1.02–8.99)2.35 (0.74–7.49)
 368/1281.14 (0.73–1.77)1.20 (0.73–1.99)50/861.83 (0.98–3.42)1.88 (0.93–3.78)20/206.09 (1.94–19.09)3.47 (0.89–13.57)
 458/1340.92 (0.58–1.46)0.92 (0.52–1.60)46/851.71 (0.90–3.27)2.02 (0.94–4.33)
log20.80 (0.49–1.32)0.57 (0.30–1.10)1.58 (0.81–3.10)2.00 (0.81–4.98)9.22 (2.25–37.77)3.53 (0.58–21.53)
IGF-I/IGFBP-3 ratio
 165/1321.0050/871.0016/441.00
 279/1351.17 (0.76–1.82)36/890.69 (0.39–1.19)18/302.19 (0.77–6.19)
 353/1510.70 (0.42–1.16)43/830.85 (0.48–1.50)15/232.56 (0.85–7.73)
 485/1401.18 (0.71–1.95)45/910.82 (0.44–1.51)
log21.46 (0.92–2.30)0.82 (0.47–1.44)2.41 (0.80–7.25)
Exclude first year of follow-up
 160/1221.0045/791.0014/381.00
 267/1181.14 (0.72–1.81)35/800.76 (0.43–1.34)15/262.10 (0.66–6.67)
 352/1350.77 (0.46–1.30)37/790.79 (0.44–1.41)13/192.66 (0.82–8.67)
 477/1321.13 (0.67–1.91)42/820.87 (0.47–1.64)
log21.49 (0.93–2.40)0.85 (0.47–1.52)2.54 (0.77–8.36)
  • aCut-points for quartiles (glioma, meningioma): IGF-1: <199.60, 199.60–252.28, 252.29–313.99, ≥314.00 ng/mL; IGFBP-3: <4,074.90, 4,074.90–4,810.39, 4,810.40–5,551.89, ≥5,551.90 ng/mL; molar IGF-1/IGFBP-3 ratio: <2.08, 2.08–2.48, 2.49–2.93, ≥2.94; cut-points for tertiles (acoustic neuromas): IGF-1: <218.31, 218.31–290.01, ≥290.02 ng/mL; IGFBP-3: <4,344.40, 4,344.39–5,276.99, ≥5,277.00 ng/mL; molar IGF-1/IGFBP-3 ratio: <2.20, 2.20–2.77, ≥2.78.

  • bAnalysis matched on EPIC recruitment center, sex, age at blood donation, time of the day at blood donation, and fasting status.

  • cIGF-I adjusted for IGFBP-3 and vice versa.